PerkinElmer, Inc. (NYSE:PKI) Shares Sold by Lombard Odier Asset Management Europe Ltd

Lombard Odier Asset Management Europe Ltd cut its position in PerkinElmer, Inc. (NYSE:PKIGet Rating) by 0.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 124,051 shares of the medical research company’s stock after selling 1,000 shares during the period. Lombard Odier Asset Management Europe Ltd owned approximately 0.10% of PerkinElmer worth $21,642,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of PKI. UMB Bank N A MO acquired a new position in shares of PerkinElmer in the fourth quarter valued at about $29,000. HighTower Advisors LLC grew its holdings in PerkinElmer by 16.8% during the fourth quarter. HighTower Advisors LLC now owns 6,258 shares of the medical research company’s stock worth $1,260,000 after acquiring an additional 900 shares during the period. Aviva PLC grew its holdings in PerkinElmer by 0.7% during the fourth quarter. Aviva PLC now owns 43,465 shares of the medical research company’s stock worth $8,739,000 after acquiring an additional 300 shares during the period. TD Asset Management Inc. grew its holdings in PerkinElmer by 3.2% during the fourth quarter. TD Asset Management Inc. now owns 40,314 shares of the medical research company’s stock worth $8,106,000 after acquiring an additional 1,251 shares during the period. Finally, Citigroup Inc. grew its holdings in PerkinElmer by 36.5% during the fourth quarter. Citigroup Inc. now owns 96,544 shares of the medical research company’s stock worth $19,411,000 after acquiring an additional 25,832 shares during the period. 77.06% of the stock is owned by institutional investors and hedge funds.

PerkinElmer Stock Performance

NYSE PKI opened at $141.62 on Friday. The company has a market cap of $17.88 billion, a PE ratio of 26.52, a price-to-earnings-growth ratio of 0.39 and a beta of 1.14. The stock’s 50 day simple moving average is $145.11 and its 200-day simple moving average is $153.15. PerkinElmer, Inc. has a 1-year low of $130.13 and a 1-year high of $203.16. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.02 and a quick ratio of 1.42.

PerkinElmer (NYSE:PKIGet Rating) last released its earnings results on Monday, August 1st. The medical research company reported $2.32 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.31. The business had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.20 billion. PerkinElmer had a return on equity of 16.68% and a net margin of 13.21%. The business’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter last year, the business posted $2.83 earnings per share. As a group, equities research analysts anticipate that PerkinElmer, Inc. will post 7.83 EPS for the current fiscal year.

PerkinElmer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 11th. Investors of record on Friday, October 21st will be given a dividend of $0.07 per share. The ex-dividend date is Thursday, October 20th. This represents a $0.28 dividend on an annualized basis and a yield of 0.20%. PerkinElmer’s payout ratio is 5.24%.

Analyst Upgrades and Downgrades

PKI has been the topic of several analyst reports. Barclays raised their target price on PerkinElmer from $125.00 to $149.00 and gave the stock an “underweight” rating in a report on Tuesday, August 2nd. The Goldman Sachs Group lowered their price target on PerkinElmer from $200.00 to $175.00 and set a “neutral” rating on the stock in a research report on Thursday, July 14th. Bank of America downgraded PerkinElmer from a “buy” rating to a “neutral” rating and set a $178.00 price target on the stock. in a research report on Tuesday, August 2nd. Robert W. Baird increased their price target on PerkinElmer from $198.00 to $202.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 2nd. Finally, UBS Group started coverage on PerkinElmer in a research report on Wednesday, July 20th. They set a “buy” rating and a $160.00 price target on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $163.40.

Insider Buying and Selling

In related news, insider Daniel R. Tereau sold 5,700 shares of PerkinElmer stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $145.14, for a total transaction of $827,298.00. Following the transaction, the insider now owns 13,380 shares in the company, valued at $1,941,973.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, insider Daniel R. Tereau sold 5,700 shares of PerkinElmer stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $145.14, for a total transaction of $827,298.00. Following the transaction, the insider now owns 13,380 shares in the company, valued at $1,941,973.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Andrew Okun sold 3,173 shares of PerkinElmer stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $165.42, for a total value of $524,877.66. Following the transaction, the insider now owns 6,391 shares in the company, valued at approximately $1,057,199.22. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,898 shares of company stock worth $2,083,263. 0.52% of the stock is owned by corporate insiders.

PerkinElmer Profile

(Get Rating)

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.

See Also

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.